About 20% of Women With Earlier Stage Breast Cancer Progress to Metastatic Disease Within 20 Years

MedicalResearch.com Interview with:

Angela Mariotto PhD Chief of the Data Analytics Branch  Surveillance Research Program (SRP) Division of Cancer Control and Population Sciences National Cancer Institute 

Dr. Mariotto

Angela Mariotto PhD
Chief of the Data Analytics Branch
Surveillance Research Program (SRP)
Division of Cancer Control and Population Sciences
National Cancer Institute (NCI

MedicalResearch.com: What is the background for this study?

Response: Progressing to metastatic breast cancer (MBC) is one of the major concerns for women diagnosed with early-stage breast cancer. Before our study there were no reliable numbers on risk of metastatic breast cancer recurrence after a (non-metastatic) breast cancer diagnosis, as registries do not routinely collect this data.

Continue reading

US vs England: Where Do Lung Cancer Patients Live Longer?

MedicalResearch.com Interview with:

CT scan showing a cancerous tumor in the left lung Wikipedia image

CT scan showing a cancerous tumor in the left lung
Wikipedia image

Cary P. Gross, MD
Department of Internal Medicine
Section of General Internal Medicine
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center
National Clinician Scholars Program
Yale School of Medicine New Haven, CT 

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: In both the US and England, lung cancer is a leading cause of cancer deaths, and there is particular concern about access to high quality care among older persons in both countries. However, little is known about how the two nations compare regarding lung cancer care.

We studied over 170,000 patients with lung cancer, and found that patients in the US were more likely to be diagnosed at an early stage (25% in US vs 15% of patients in England).  Our international team also found that patients in the US were more likely to receive treatment for their cancer, and were more likely to survive.

Continue reading

Younger Colon Cancer Patients Receive More Chemotherapy But No Greater Survival Benefit

MedicalResearch.com Interview with:
Kangmin Zhu, PhD, MD

John P. Murtha Cancer Center, Walter Reed National Military Medical Center
Professor at the Uniformed Services University of the Health Sciences in the
Department of Preventive Medicine and Biostatistics
Bethesda, Maryland

MedicalResearch.com: What is the background for this study?

Response: An article published on JAMA Surgery in 2015 showed more utilization of chemotherapy among young colon cancer patients.  To demonstrate the study findings, we analyzed the data from the Department of Defense healthcare system, in which all members have the same level of access to medical care and therefore the potential effects of insurance status and types on research results can be reduced.

MedicalResearch.com: What are the main findings?

Response: The main findings were that young and middle-aged colon cancer patients were 2 to 8 times more likely to receive postoperative chemotherapy and 2.5 times more likely to receive multiagent regimens, compared with their counterparts aged 65 to 75 years.  However, no matched survival benefits were observed for the young and middle-aged among patients who received surgery and postoperative chemotherapy.

Continue reading